JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) (“Teva”) announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion (approximately USD 1.2 billion) senior unsecured fixed-rate syndicated term loan facility.